[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604442":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":11,"locations":17,"responsibleParty":34,"collaborators":10,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":41,"acronym":10,"eligibilityCriteria":42,"healthyVolunteers":43,"sex":44,"minAge":10,"maxAge":10,"enrollmentInfo":45,"targetDuration":10,"studyType":48,"phases":10,"briefSummary":49,"conditions":50,"keywords":53,"overallStatus":20,"whyStopped":10,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},{"fullName":5,"class":6},"Tongji Hospital","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":10},"Metabolic-Associated Fatty Liver Disease patients",null,[12],{"name":13,"role":14,"phone":15,"phoneExt":10,"email":16},"Zhen Li","CONTACT","02783663543","zhenli@hust.edu.cn",[18],{"facility":19,"status":20,"city":21,"state":22,"zip":10,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"Tongji hospital","RECRUITING","Wuhan","Hubei","China","CN",{"type":26,"coordinates":27},"Point",[28,29],114.26667,30.58333,{"lat":29,"lon":28},[32],{"name":13,"role":14,"phone":33,"phoneExt":10,"email":16},"+862783663543",{"type":35,"investigatorFullName":13,"investigatorTitle":36,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Professor","100604442","to-explore-the-value-of-new-mr-technology-in-non-invasive-quantitative-assessment-of-systemic-metabolism-disease-status-and-prognosis-in-patients-with-metabolic-associated-fatty-liver-disease-100604442",false,"NCT07149571","To Explore the Value of New MR Technology in Non-invasive Quantitative Assessment of Systemic Metabolism, Disease Status and Prognosis in Patients With Metabolic-Associated Fatty Liver Disease","Inclusion Criteria:\n\n1. Patients with MR examination are clinically suspected or diagnosed with metabolism-related fatty liver disease;\n2. Age\u002Fgender: unlimited;\n3. Patients who voluntarily participate in clinical trials and sign written subject informed consent\n\nExclusion Criteria:\n\n1. Clinical suspicion or diagnosis of metabolism-related fatty liver disease and having been prescribed an MR examination;\n2. Voluntarily participation in the study and provision of written informed consent.",true,"ALL",{"count":46,"type":47},500,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to explore the value of new MR technology in assessing the systemic metabolism, disease status, and prognostic risk of metabolism-related fatty liver disease. By obtaining clinical, imaging, laboratory examination and pathological data of metabolism-related fatty liver disease, image processing software is used to analyze the images, explore the relationship between imaging parameters, body composition and metabolic diseases and metabolism-related fatty liver disease, and achieve non-invasive diagnosis, efficacy evaluation, and prognosis prediction of metabolism-related fatty liver disease. Thereby guiding clinical treatment and improving the prognosis and quality of life of patients with metabolism-related fatty liver disease",[51,52],"Nonalcoholic Fatty Liver Disease","Metabolic-associated Fatty Liver Disease",[54],"MRI, metabolism-related fatty liver disease","2025-08-29",{"date":57,"type":58},"2025-09-02","ACTUAL",{"date":60,"type":58},"2025-04-01",{"date":62,"type":47},"2032-12-31",{"name":5,"class":6},1]